Weighing | Anda Tang ® heart failure in China was approved

AstraZeneca Anda Tang ® (common name: Dagley Net) has been officially approved in China for the treatment of adult patients with reduced blood test scores (HFrEF, NYHA II-IV), which reduces the risk of cardiovascular death and hospitalization for heart failure (hHF).
chronic heart failure is a fatal disease that can lead to decreased blood function in the heart pump, which is difficult to meet the body's needs1.
at least half of these patients are shot fractional reduction type heart failure (HFrEF)2, which usually manifests it as a failure of the left cercardial heart muscle to contract sufficiently, reducing the blood supply to circulatory and exozos by 3-5.
daglie's approval in China is based on positive results from the landmark DAPA-HF III clinical trial published in the New England Journal of Medicine.
May 2020, china's State Drug Administration (NMPA) Drug Review Center (CDE) included DAPA-HF research in its priority review.
Professor Ge Junbo, Fellow of the Chinese Academy of Sciences, Director of Cardiovascular Medicine at Sun Yat-sen Hospital affiliated with Fudan University, and Chief Researcher of DAPA-HF Clinical Research in China, "The mortality rate of cardiovascular disease in China far exceeds that of cancer and other diseases, and is the first cause of death to harm the population."
30 research centers in China were selected for the DAPA-HF study, and the results strongly support the approval of Dagle Net in China as a new treatment standard that will benefit tens of millions of Chinese heart failure patients.
" Mene Pangalos AstraZenecon Global Executive Vice President Biopharmaceutical Research and Development "In addition to heart transplants, there is currently no known cure for chronic heart failure, so patients urgently need a new treatment that improves symptoms and prolongs life."
tens of millions of heart failure patients around the world, and our ambition is to find treatments that improve their prognostication.
, this approval is significant.
" Wang Lei AstraZenecon Global Executive Vice President of International Business and President of China" Dagli Net's approval will provide new treatment options for heart failure patients in China and further confirm its ability to treat diabetes and heart failure.
will continue to accelerate the development and introduction of innovative drugs to meet the needs of the vast majority of people with chronic diseases, taking into care the needs of patients.
" Dr. He Jing, President of AstraZene couture's Global Research and Development China Center, is committed to breaking through the scientific community and exploring potential links across disease areas.
Dagledge is the first SGLT2 inhibitor in China to be officially approved for heart failure adaptation, significantly reducing cardiovascular death and worsening heart failure events, a approval that will redefine existing treatment standards and bring new hope to tens of millions of people with heart failure in China.
"DAPA-HF III clinical trial DAPA-HF III clinical trials have shown that the addition of Dagle net to standard treatments (including ACEi or ARB) reduces the risk of cardiovascular death or heart failure exacerbation events (including heart failure hospital hHF) complex endpoint outcomes by 26% compared to placebos, and that the two components that make up the main compound therapy endpoints are helpful for overall efficacy6.
is the first SGLT2 inhibitor to have this effect.
the safety of phase DPA-HF III clinical trials is consistent with the known safety of the drug.
during the trial, one cardiovascular death or heart failure hospitalization or one emergency visit associated with heart failure could be avoided for every 21 patients treated.
has been approved in the United States, Europe, Japan and many countries and regions around the world for adult blood test score reduction heart failure treatment.
scientific research continues to find a close link between the heart, kidneys and pancreas, AstraZenecon's research on the prevention of heart and kidney events at Dagrid is advancing.
DAPA-HF is part of DapaCare's complete clinical research program to assess the potential of Daglyn net for cardiovascular and kidney benefits.
the program also explores Dagley Net's performance in the field of chronic kidney disease, and in August 2020, the DAPA-CKD III clinical trial published full results showing that Dagrid Net reached all major and secondary endpoints, including reducing all-cause mortality.
addition, in the DELIVER PHASE III clinical trial, Dagrin is currently being tested in patients with HFpEF heart failure, with data expected to be released in the second half of 2021.
ongoing DAPA-MI III clinical study, which was conducted in patients with acute heart attack (MI) or heart attack without type 2 diabetes, was the first randomized controlled study of its kind to attempt an adaptation registration study.
about heart failure Heart failure (HF) affects about 64 million people worldwide (at least half of whom are blood-cell-reduced heart failure) 2,7, including 15 million in the European Union, 6 million in the United States, 8,9 and 7 million treated adult heart failure patients in China.
heart failure is a chronic disease, with more than half of patients dying within five years of diagnosis.
The heart failure is divided into two broad categories based on the value of the shot fraction (EF: i.e. the percentage of the volume of the end-of-cardiac throbbing output per fight): the shot fraction reduction heart failure (HFrEF) and the shot fraction reserved heart failure (HFpEF)3.
of the lower blood score of the blood cell showed that the left cercardial heart muscle did not contract sufficiently, resulting in a reduction in the blood supply of circulatory and exoskeletosis tissue by 4,5.
Heart failure is as deadly as some of the most common cancers in men (prostate and bladder cancer) and women (breast cancer)12, and is the main reason for hospitalization for patients over 65 years of age, facing a huge clinical burden on doctors and a huge financial burden on patients.13
About DAPA-HF Research DAPA-HF (The Adverse Results of Dagle Net Prevention of Heart Failure) is an international, multi-center, parallel grouping, randomized, double-blind Phase III clinical trial that selected 4,744 patients with reduced blood test scores (LVEF≤40%) with or without type 2 diabetes.
the trial was designed to assess the efficacy of using daglyceda 10mg once a day on a standard basis compared to placebo.
major compound endpoints are the first heart failure exacerbation events (hospitalization or equivalent events, such as emergency heart failure) or cardiovascular death.
follow-up time was 18.2 months.
about Dagle Net Dagrid is the first sodium-glucose co-transport protein-2 (SGLT2) inhibitor of its kind, once a day or oral.
as scientific research continues to discover potential relationships between the heart, kidneys and pancreas, Dagrid's research has evolved from the effects of benefiting the heart and kidneys to the prevention of heart and kidney disease and organ protection.
damage to individual human organs can lead to corresponding failure of other organs, which is the leading cause of death worldwide, including type 2 diabetes, heart failure and chronic kidney disease.
nearly a decade ago, the effects of Dagled's net have been reflected in both single-drug and combined therapist treatments, improving blood sugar control in adults with type 2 diabetes based on diet and exercise.
landmark DECLARE-TIMI 58 study confirmed that the addition of daglycem to standard treatments can effectively reduce the risk of hospitalization (hHF) or cardiovascular death in adults with type 2 diabetes.
is also the first SGLT2 inhibitor approved for adult patients with reduced blood test scores, regardless of whether they are associated with type 2 diabetes.
In August 2020, the full results of the DAPA-CKD III clinical trial showed that Dagrid had unprecedented efficacy in reducing the compound risk of kidney failure and cardiovascular or kidney death in patients with chronic kidney disease compared to the placebo group.
trials of kidney prognostics in the patient population of the disease, Dagledge has become the first SGLT2 inhibitor to significantly prolong a patient's life and provide organ protection.
, Dagly's net chronic kidney disease adaptation has not yet been approved.
DapaCare is a complete clinical trial program designed to assess the potential benefits of Daglyn in the cardiovascular and kidney fields.
program includes 35 completed and ongoing Phase IIb/III clinical trials, including more than 35,000 patients, with more than 2.5 million years of experience.
currentLYVER III trial is currently evaluating patients with resuming blood fractional heart failure.
in the DAPA-MI III trial, Dagly net studied patients with acute heart attack (MI) or heart attack who did not combine type 2 diabetes, the first randomized controlled study of its kind to attempt an adaptation registration study.